ArticleThe FEBS journal2025
ZNF224 enhances the oncogenic function of p21 via p53 and AKT pathways in melanoma.
Article in The FEBS journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dihydroxyacetone nanoparticles ameliorate osteoarthritis via P21-mediated regulation of chondrocyte repair.Journal of nanobiotechnology · 2026Article
- A Strategy for Single-Run Sequencing of the Water Buffalo Genome: (II) Fast One-Step Assembly of Highly Continuous Chromosome Sequences.Animals : an open access journal from MDPI · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Expression of zinc finger protein 224 (ZNF224) is deregulated in various hematological and solid cancers, where its high protein levels correlate well with faster progression and worse prognosis due to activation of oncogenic pathways involved in promoting cell growth and survival, inhibiting apoptosis, and sustaining invasion and metastasis. In previous works, we identified ZNF224 as one of the mediators of the transforming growth factor beta (TGF-β)-induced pro-tumoral activities in melanoma. In the present study, we thoroughly investigated the molecular mechanisms underlying the oncogenic role of ZNF224 in this kind of cancer. We demonstrated that ZNF224 overexpression caused increased cell growth and reduced drug-mediated apoptosis by enhancing the dysregulated function of cyclin-dependent kinase inhibitor 1 [p21(CIP1/WAF1), also known as CDKN1A]. We provide strong evidence that ZNF224 overexpression in melanoma cell lines positively modulated p21(CIP1/WAF1) gene transcription in a p53-dependent manner and enhanced AKT-triggered p21(CIP1/WAF1) oncogenic effects through its protein cytosolic retention, inhibiting apoptosis and favoring cell proliferation. Analysis of transcriptomic data from human melanoma tissue samples confirmed a close relationship between p21(CIP1/WAF1) and ZNF224 in cells, at least as long as p53 functionality is maintained. The tumorigenic molecular mechanism involving ZNF224, identified in this study, provides new insights into understanding melanoma development and progression, breaking ground in the research for new therapeutic tools.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.